The ODN delivers insights into how anti-cancer medicines are being used in today’s clinical practice, in which patient groups, for which tumours and in what combination or sequence. These insights also include “pragmatic outcomes” (outcomes that can be captured at scale and in near-real time), such as duration of treatment, cycles completed and early discontinuation.
The ODN infrastructure enables data transmission from all participating centers across Europe within 24 hours. This speed is essential to accelerate clinical research and to help identify patient eligibility for trials and studies. Information from the ODN will also support biopharmaceutical companies to independently develop novel payment agreements that help to ensure continued access to innovative medicines.
The hospitals that are already participating in this initiative are aware of the value of this type of shared network, to improve decision-making, the quality of care provided and to help the financial sustainability of the healthcare system.
Dr Enrique Grande, Head of the Medical Oncology Service at MD Anderson Cancer Centre Madrid, Spain and Member of the Spain Advisory Group
The ODN is more than just a technology solution, it is a multi-stakeholder collaboration. At the start of the initiative, IQVIA established the Collaboration for Oncology Data in Europe (CODE) involving patient organizations, healthcare professionals, and industry and policy makers. IQVIA also put in place a robust governance framework, led by an external board of clinical advisors, to ensure the network meets the needs of the broader oncology community. There are ongoing opportunities for a variety of stakeholders to be actively involved in the collaboration.
The ODN was built following the principles of “data protection by design” to ensure privacy and security. Clinical teams continue working with their current systems, while the ODN platform aggregates non-identified treatment data from all participating centers and automatically maps and translates this data to make it comparable.
Clinicians can use the near real-time analyses available via the ODN to reflect on current practice at a local, national or European level. Treatment centers joining the ODN have access to an analytical dashboard and can generate insights into how similar patients are being treated and what pragmatic outcomes are being achieved. These insights can help inform best practices and highlight variations in care, as well as help to accelerate clinical research.
The only way to understand the degree of variation in front-line cancer care – and enable development of strategies to improve quality and iron out inconsistencies and inequalities – is to come together and share data in a structured, systematic way.
PROFESSOR DAVID KERR, PROFESSOR OF CANCER MEDICINE AT THE UNIVERSITY OF OXFORD, ENGLAND, CHAIR OF CODE’S CLINICAL AND ANALYTICAL STEERING COMMITTEE
The ODN aims to improve our understanding of cancer treatment practice across Europe. It will provide insights into the actual real world use of increasingly specialized therapies. An additional use of the ODN, which stems from this capability, is to support the development of new payment models by biopharmaceutical companies. This may help address the financial considerations associated with the use of anti-cancer medicines. And ultimately, it will help enable healthcare systems to maximize the value of cancer treatment, while facilitating access to innovative new therapies. This initiative is another example of a pioneering program IQVIA is building to help inform and accelerate global research, healthcare partnerships and patient access to medicines.
Tap into evidence networks in oncology, neurology, immunology, and other therapy areas to enrich your studies.
Access a dedicated network of European cancer hospitals to capture real world data that reflects the latest clinical practice and perform oncology studies faster.